Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENOV Enovis	$30.90 -3.3%	$32.87	$28.83 ▼ $49.83	$1.83B	1.7	908,943 shs	1.56 million shs
LMAT LeMaitre Vascular	$82.23 -2.2%	$82.79	$71.42 ▼ $109.58	$1.90B	0.82	169,710 shs	135,033 shs
NVCR NovoCure	$16.79 -3.6%	$17.66	$14.17 ▼ $34.13	$1.94B	0.72	1.12 million shs	740,350 shs
RXST RxSight	$7.45 -3.7%	$13.70	$6.32 ▼ $58.23	$314.53M	1.21	808,139 shs	1.94 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENOV Enovis	-3.15%	-11.05%	-3.01%	-0.68%	-30.93%
LMAT LeMaitre Vascular	-2.21%	-2.00%	+1.36%	-2.88%	-4.73%
NVCR NovoCure	-3.62%	-4.11%	-4.33%	+6.06%	-6.67%
RXST RxSight	-3.75%	-41.75%	-47.57%	-48.69%	-84.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENOV Enovis	2.4568 of 5 stars	3.4	1.0	0.0	0.0	1.5	1.7	1.9
LMAT LeMaitre Vascular	2.4715 of 5 stars	2.2	1.0	3.3	0.0	2.3	2.5	1.3
NVCR NovoCure	3.5167 of 5 stars	3.4	1.0	0.0	4.5	2.0	1.7	0.0
RXST RxSight	2.2315 of 5 stars	4.0	1.0	0.0	0.0	1.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENOV Enovis	2.80	Moderate Buy	$55.60	79.94% Upside
LMAT LeMaitre Vascular	2.33	Hold	$97.83	18.98% Upside
NVCR NovoCure	2.71	Moderate Buy	$32.43	93.14% Upside
RXST RxSight	1.91	Reduce	$17.50	134.90% Upside

Current Analyst Ratings Breakdown

Latest RXST, NVCR, ENOV, and LMAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	RXST RxSight	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $9.00
7/10/2025	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$24.00 ➝ $9.00
7/9/2025	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $9.00
7/9/2025	RXST RxSight	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $10.00
7/9/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $9.00
7/9/2025	RXST RxSight	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/9/2025	RXST RxSight	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$25.00 ➝ $9.00
7/9/2025	RXST RxSight	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
7/9/2025	RXST RxSight	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/8/2025	ENOV Enovis	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$48.00 ➝ $46.00
7/8/2025	NVCR NovoCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENOV Enovis	$2.11B	0.84	$18.61 per share	1.66	$45.10 per share	0.69
LMAT LeMaitre Vascular	$219.86M	8.45	$2.34 per share	35.20	$15.00 per share	5.48
NVCR NovoCure	$605.22M	3.09	N/A	N/A	$3.33 per share	5.04
RXST RxSight	$139.93M	2.16	N/A	N/A	$6.98 per share	1.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENOV Enovis	-$825.49M	-$13.95	N/A	9.69	N/A	-37.65%	5.99%	3.44%	8/6/2025 (Estimated)
LMAT LeMaitre Vascular	$44.04M	$1.98	41.53	37.89	2.22	19.96%	13.53%	9.78%	8/5/2025 (Estimated)
NVCR NovoCure	-$168.63M	-$1.51	N/A	N/A	N/A	-26.41%	-45.46%	-13.34%	7/24/2025 (Estimated)
RXST RxSight	-$27.45M	-$0.67	N/A	N/A	N/A	-17.90%	-9.54%	-8.51%	8/7/2025 (Estimated)

Latest RXST, NVCR, ENOV, and LMAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Guidance Update	RXST RxSight	-$0.0363	N/A	N/A	N/A	$39.78 million	N/A
8/6/2025	Q2 2025	ENOV Enovis	$0.74	N/A	N/A	N/A	$555.80 million	N/A
8/5/2025	Q2 2025	LMAT LeMaitre Vascular	$0.57	N/A	N/A	N/A	$62.48 million	N/A
7/24/2025	Q2 2025	NVCR NovoCure	-$0.40	N/A	N/A	N/A	$153.87 million	N/A
5/8/2025	Q1 2025	ENOV Enovis	$0.74	$0.81	+$0.07	-$0.98	$558.80 million	$558.83 million
5/7/2025	Q1 2025	RXST RxSight	-$0.03	-$0.03	N/A	-$0.20	$38.74 million	$37.90 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENOV Enovis	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.97%	N/A	40.40%	14 Years
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A

Latest RXST, NVCR, ENOV, and LMAT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENOV Enovis	0.52	2.55	1.32
LMAT LeMaitre Vascular	0.48	16.49	13.83
NVCR NovoCure	0.27	1.47	1.41
RXST RxSight	N/A	12.68	11.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENOV Enovis	98.45%
LMAT LeMaitre Vascular	84.64%
NVCR NovoCure	84.61%
RXST RxSight	78.78%

Insider Ownership

Company	Insider Ownership
ENOV Enovis	2.70%
LMAT LeMaitre Vascular	9.50%
NVCR NovoCure	5.52%
RXST RxSight	9.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENOV Enovis	7,367	57.12 million	55.58 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.45 million	Optionable
NVCR NovoCure	1,488	111.49 million	105.33 million	Optionable
RXST RxSight	220	40.64 million	36.75 million	Optionable

RXST, NVCR, ENOV, and LMAT Headlines

Recent News About These Companies

Morgan Stanley Downgrades RxSight (RXST)

2 hours ago | msn.com

RXSIGHT ALERT: Bragar Eagel & Squire, P.C.Announces Investigation into RxSight, Inc. (RXST) and Encourages Investors to Contact the Firm

July 15 at 9:34 PM | globenewswire.com

Robbins LLP is Investigating the Officers and Directors of RxSight, Inc. (RXST) to Determine if They Breached Fiduciary Duties Owed to Shareholders

July 15 at 5:43 PM | globenewswire.com

Morgan Stanley Downgrades RxSight (NASDAQ:RXST) to Equal Weight

July 15 at 9:03 AM | marketbeat.com

RxSight (NASDAQ:RXST) Earns Hold Rating from Jefferies Financial Group

July 13 at 2:27 AM | americanbankingnews.com

Brokerages Set RxSight, Inc. (NASDAQ:RXST) PT at $30.20

July 13 at 2:41 AM | americanbankingnews.com

RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices ...

July 12, 2025 | businesswire.com

Securities Fraud Investigation Into RxSight, Inc. (RXST) Announced ...

July 12, 2025 | morningstar.comM

RxSight, Inc. (RXST) Investors Who Lost Money - Morningstar

July 12, 2025 | morningstar.comM

Bank of America Cuts RxSight (NASDAQ:RXST) Price Target to $9.00

July 12, 2025 | americanbankingnews.com

RxSight's (RXST) Buy Rating Reiterated at Needham & Company LLC

July 12, 2025 | americanbankingnews.com

RxSight's (RXST) Neutral Rating Reiterated at BTIG Research

July 12, 2025 | americanbankingnews.com

RxSight (NASDAQ:RXST) Lowered to "Sell" Rating by Wall Street Zen

July 12, 2025 | marketbeat.com

INVESTOR ALERT: Investigation of RxSight, Inc. (RXST) Announced by Holzer & Holzer, LLC

July 11, 2025 | globenewswire.com

Securities Fraud Investigation Into RxSight, Inc. (RXST) Announced â€“ Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

July 11, 2025 | businesswire.com

RxSight Stock Sinks 50% as Medical Device Maker Slashes ... - Investopedia

July 11, 2025 | investopedia.com

Securities Fraud Investigation Into RxSight, Inc. (RXST) Announced - Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

July 11, 2025 | tmcnet.com

Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. (RXST) Shareholders

July 11, 2025 | globenewswire.com

RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 11, 2025 | businesswire.com

RxSight (NASDAQ:RXST) Given New $10.00 Price Target at Piper Sandler

July 11, 2025 | americanbankingnews.com

RxSight (NASDAQ:RXST) Given New $9.00 Price Target at Stifel Nicolaus

July 11, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Enovix Shares Hit 6-Month High; Long-Term Highs to Follow
By Thomas Hughes | July 10, 2025
View Enovix Shares Hit 6-Month High; Long-Term Highs to Follow

RXST, NVCR, ENOV, and LMAT Company Descriptions

Enovis NYSE:ENOV

$30.90 -1.06 (-3.32%)

Closing price 07/15/2025 03:59 PM Eastern

Extended Trading

$30.90 0.00 (-0.02%)

As of 07/15/2025 07:49 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

LeMaitre Vascular NASDAQ:LMAT

$82.23 -1.86 (-2.21%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$82.22 -0.01 (-0.01%)

As of 07/15/2025 04:20 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NovoCure NASDAQ:NVCR

$16.79 -0.63 (-3.62%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$16.98 +0.19 (+1.10%)

As of 07:01 AM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

RxSight NASDAQ:RXST

$7.45 -0.29 (-3.75%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$7.45 0.00 (-0.05%)

As of 07:00 AM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time